Early TB and Lung Cancer Diagnostics Pace Diagnostics focuses on point-of-care diagnostics with lead developments in tuberculosis and early detection of lung cancer, presenting a clear entry point for partnerships, licensing, and co-development with larger clinical lab networks and pharma entities seeking rapid, decentralized testing capabilities.

High-Growth Market Fit With a revenue range of 1M to 10M and operating in biotechnology research, Pace Diagnostics sits in a scalable segment where partnerships with mid-to-large reference labs and hospital systems could amplify adoption of their POC platform, leveraging existing grant-funded research credibility.

Strategic Licensing Opportunities The company’s emphasis on licensing, manufacturing, and marketing of diagnostics indicates a ready path for business development through technology licensing deals, exclusive rights in regional markets, or joint ventures with established diagnostics distributors.

Digital Presence with Marketing Enablement Current tech stack suggests a modern, web-enabled go-to-market approach. Sales motions can leverage digital marketing collaboration, partner portals, and lead generation through WordPress/WooCommerce and analytics to identify and nurture potential customers in labs and clinics.

Competitive Landscape Readiness Operating alongside large reference labs and diagnostics players implies a need to articulate differentiators such as high-throughput POC capabilities, biomarker potency, and grant-backed innovation to win collaborations, channel partnerships, and competitive tenders.